Distribusion Technologies | $80,000,000 | (Sep 27, 2024)
Cytix | $2,143,528 | (Sep 27, 2024)
Convergence | $12,000,000 | (Sep 27, 2024)
PineTree Therapeutics Inc
United States
- Cambridge, Massachusetts
- 31/07/2024
- Series A
- $17,000,000
Pinetree Therapeutics is an award-winning, pre-clinical stage biotechnology company based in Cambridge, Massachusetts. Dedicated to addressing unmet medical needs, such as drug resistance and tumor recurrence in targeted therapy, Pinetree Therapeutics is advancing the field with its novel AbReptorTM platform. While the primary focus is on oncology, Pinetree Therapeutics is expanding pipelines to other areas as well.
The AbReptorTM platform enables the development of multi-specific antibodies designed to outperform conventional inhibitors and ADCs (Antibody Drug Conjugate) by degradation. Unlike traditional inhibitors, which are limited in their mechanism of action (blocking the signaling pathway), our antibodies demonstrate superior efficacy in targeting and degrading disease proteins. The platform's focus is on targeted degradation of membrane-bound and extracellular proteins, offering a distinct advantage over conventional inhibitors and intracellular degraders like PROTACs or GLUEs. Additionally, the unique mechanism of our platform has yielded promising preclinical results in ADC (/DAC/ARC) application, demonstrating its potential to significantly advance the field.
- Industry Biotechnology
- Website https://www.pinetreetx.com/
- LinkedIn https://www.linkedin.com/company/pinetree-therapeutics/
Related People
Ho-Juhn SongFounder
United States -
Greater Boston
I am a passionate drug hunter who has a practical and in-depth understanding of all the requirements and processes needed to advance drugs through discovery and into development from target selection/validation to lead identification to lead optimization, through safety/toxicity assessment, into clinical development. Successfully generating 3 drug candidates in clinical trials in the US; two Ph1/2 oncology drugs and one Ph2 immunology drug. Creative thinker and doer with proactive project/risk management and translational approach to achieve short- and long-term goal of the company. Practical experience in licensing activity and forward strategy with flexibility for business development and licensing.
I am really looking forward to the next challenging drug program with the new therapeutic opportunity.
SURGAR | $12,288,870 | (Sep 27, 2024)
Quorum | Undisclosed Amount | (Sep 27, 2024)
Prepared | $27,000,000 | (Sep 27, 2024)
AmpUp | $15,000,000 | (Sep 27, 2024)
HighFive | $250,000 | (Sep 27, 2024)
Tetrix | $5,000,000 | (Sep 27, 2024)
The Curling Group | $5,000,000 | (Sep 27, 2024)
AminoChain | $5,000,000 | (Sep 27, 2024)
Gladly | $40,000,000 | (Sep 27, 2024)